Esolinda

Esolinda 20 mg:

Each enteric coated tablet contains:

• Esomeprazole Magnesium USP (As Trihydrate) eq. to Esomeprazole 20 mg.
• Approved colours used in coating

Esolinda 40 mg:

Each enteric coated tablet contains:

• Esomeprazole Magnesium USP (As Trihydrate) eq. to Esomeprazole 40 mg.
• Approved colours used in coating

Should be used with the following indications:

• Gastroesophageal reflux disease (GORD): Treatment of erosive reflux oesophagitis, Long-term management of patients with healed oesophagitis to prevent relapse, Symptomatic treatment of gastroesophageal reflux disease (GORD);
• In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori: Healing of Helicobacter pylori associated duodenal ulcer, prevention of relapse of peptic ulcers in patients with Helicobacter pyloriassociated ulcers;
• Patients requiring continued NSAID therapy: Healing of gastric ulcers associated with NSAID therapy, Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk, Prolonged treatment after IV induced prevention of rebleeding of peptic ulcers.
• Treatment of Zollinger Ellison Syndrome;

Adolescents from the age of 12 years:

• Gastro-Oesophageal Reflux Disease (GORD): treatment of erosive reflux oesophagitis, long-term management of
• patients with healed oesophagitis to prevent relapse, symptomatic treatment of gastro-oesophageal reflux disease (GORD).
• In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori.

The tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed. For patients who have difficulty in swallowing, the tablets can also be dispersed in half a glass of non-carbonated water. No other liquids should be used, as the delayed release may be dissolved. Stir until the tablets disintegrate and drink the liquid with the pellets immediately or within 30 minutes. Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.

For patients who cannot swallow, the tablets can be dispersed in non-carbonated water and administered through a gastric tube. It is important that the appropriateness of the selected syringe and tube is carefully tested.

Administration through gastric tube:

1. Put the tablet into an appropriate syringe and fill the syringe with approximately 25 ml water and approximately 5 ml air. For some tubes, dispersion in 50 mL water is needed to prevent the pellets from clogging the tube.
2. Immediately shake the syringe for approximately 2 minutes to disperse the tablet.
3. Hold the syringe with the tip up and check that the tip has not clogged.
4. Attach the syringe to the tube whilst maintaining the above position.
5. Shake the syringe and position it with the tip pointing down. Immediately inject 5–10 mL into the tube. Invert the syringe
after injection and shake (the syringe must be held with the tip pointing up to avoid clogging of the tip).
6. Turn the syringe with the tip down and immediately inject another 5–10 mL into the tube. Repeat this procedure until the syringe is empty.
7. Fill the syringe with 25 mL of water and 5 mL of air, and repeat step 5 if necessary to wash down any sediment left in the syringe. For some tubes, 50 mL water is needed.

Adults and adolescents from the age of 12 years.

Gastro-oesophageal Reflux Disease (GORD) – Treatment of erosive reflux oesophagitis – 40 mg once daily for 4 weeks.

An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or who have persistent symptoms.

Long-term management of patients with healed oesophagitis to prevent relapse – 20 mg once daily.

Symptomatic treatment of gastro-oesophageal reflux disease (GORD) – 20 mg once daily in patients without oesophagitis.